Compare Adaptive Biotechnologies Corp (ADPT) vs Danaos Corporation (DAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Danaos Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.08 (market cap $3.33B), while Danaos Corporation trades at $126.58 (market cap $2.27B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Danaos Corporation pays a 2.88% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DAC | |
|---|---|---|
Market Cap | $3.33B | $2.27B |
Sector | Health | Technology |
52-Week High | $22.37 | $134.63 |
52-Week Low | $10.24 | $84.05 |
Enterprise Value | $3.19B | $2.28B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Danaos Corporation (DAC) trades at $125.34, up 2.47% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.42 and net income margin near 50%, supported by consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, with Q2 2026 results pending.
Outlook remains positive due to deep value metrics and robust cash flow, but risks include cyclical shipping demand and capital expenditure pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
